Ortho Biotech
Executive Summary
Will operate as a separate company of Johnson & Johnson headed by Dennis Longstreet as president. The operation was previously a division of the J&J subsidiary, Ortho Pharmaceutical. Longstreet has been president of the division since early 1986. Ortho Biotech markets Orthoclone OKT-3 for reverse acute kidney transplantation rejection in the U.S. and sells Eprex (EPO) through J&J subsidiaries in 36 countries outside the U.S.